Cargando…

Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis

Beyond being a key factor for tumor growth and metastasis in human cancer, C-X-C motif chemokine receptor 4 (CXCR4) is also highly expressed by a number of immune cells, allowing for non-invasive read-out of inflammatory activity. With two recent studies reporting on prognostic implications of the s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kraus, Sabrina, Klassen, Philipp, Kircher, Malte, Dierks, Alexander, Habringer, Stefan, Gäble, Alexander, Kortüm, Klaus Martin, Weinhold, Niels, Ademaj-Kospiri, Valëza, Werner, Rudolf A, Schirbel, Andreas, Buck, Andreas K, Herhaus, Peter, Wester, Hans-Jürgen, Rosenwald, Andreas, Weber, Wolfgang A, Einsele, Hermann, Keller, Ulrich, Rasche, Leo, Lapa, Constantin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373803/
https://www.ncbi.nlm.nih.gov/pubmed/35966583
http://dx.doi.org/10.7150/thno.75847
_version_ 1784767664276635648
author Kraus, Sabrina
Klassen, Philipp
Kircher, Malte
Dierks, Alexander
Habringer, Stefan
Gäble, Alexander
Kortüm, Klaus Martin
Weinhold, Niels
Ademaj-Kospiri, Valëza
Werner, Rudolf A
Schirbel, Andreas
Buck, Andreas K
Herhaus, Peter
Wester, Hans-Jürgen
Rosenwald, Andreas
Weber, Wolfgang A
Einsele, Hermann
Keller, Ulrich
Rasche, Leo
Lapa, Constantin
author_facet Kraus, Sabrina
Klassen, Philipp
Kircher, Malte
Dierks, Alexander
Habringer, Stefan
Gäble, Alexander
Kortüm, Klaus Martin
Weinhold, Niels
Ademaj-Kospiri, Valëza
Werner, Rudolf A
Schirbel, Andreas
Buck, Andreas K
Herhaus, Peter
Wester, Hans-Jürgen
Rosenwald, Andreas
Weber, Wolfgang A
Einsele, Hermann
Keller, Ulrich
Rasche, Leo
Lapa, Constantin
author_sort Kraus, Sabrina
collection PubMed
description Beyond being a key factor for tumor growth and metastasis in human cancer, C-X-C motif chemokine receptor 4 (CXCR4) is also highly expressed by a number of immune cells, allowing for non-invasive read-out of inflammatory activity. With two recent studies reporting on prognostic implications of the spleen signal in diffusion-weighted magnetic resonance imaging in patients with plasma cell dyscrasias, the aim of this study was to correlate splenic (68)Ga-Pentixafor uptake in multiple myeloma (MM) with clinical parameters and to evaluate its prognostic impact. Methods: Eighty-seven MM patients underwent molecular imaging with (68)Ga-Pentixafor-PET/CT. Splenic CXCR4 expression was semi-quantitatively assessed by peak standardized uptake values (SUV(peak)) and corresponding spleen-to-bloodpool ratios (TBR) and correlated with clinical and prognostic features as well as survival parameters. Results: (68)Ga-Pentixafor-PET/CT was visually positive in all MM patients with markedly heterogeneous tracer uptake in the spleen. CXCR4 expression determined by (68)Ga-Pentixafor-PET/CT corresponded with advanced disease and was inversely associated with the number of previous treatment lines as compared to controls or untreated smouldering multiple myeloma patients (SUV(peak)Spleen 4.06 ± 1.43 vs. 6.02 ± 1.16 vs. 7.33 ± 1.40; P < 0.001). Moreover, reduced splenic (68)Ga-Pentixafor uptake was linked to unfavorable clinical outcome. Patients with a low SUV(peak)Spleen (<3.35) experienced a significantly shorter overall survival of 5 months as compared to 62 months in patients with a high SUV(peak)Spleen >5.79 (P < 0.001). Multivariate Cox analysis confirmed SUV(peak)Spleen as an independent predictor of survival (HR 0.75; P = 0.009). Conclusion: These data suggest that splenic (68)Ga-Pentixafor uptake might provide prognostic information in pre-treated MM patients similar to what was reported for diffusion-weighted magnetic resonance imaging. Further research to elucidate the underlying biologic implications is warranted.
format Online
Article
Text
id pubmed-9373803
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-93738032022-08-12 Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis Kraus, Sabrina Klassen, Philipp Kircher, Malte Dierks, Alexander Habringer, Stefan Gäble, Alexander Kortüm, Klaus Martin Weinhold, Niels Ademaj-Kospiri, Valëza Werner, Rudolf A Schirbel, Andreas Buck, Andreas K Herhaus, Peter Wester, Hans-Jürgen Rosenwald, Andreas Weber, Wolfgang A Einsele, Hermann Keller, Ulrich Rasche, Leo Lapa, Constantin Theranostics Research Paper Beyond being a key factor for tumor growth and metastasis in human cancer, C-X-C motif chemokine receptor 4 (CXCR4) is also highly expressed by a number of immune cells, allowing for non-invasive read-out of inflammatory activity. With two recent studies reporting on prognostic implications of the spleen signal in diffusion-weighted magnetic resonance imaging in patients with plasma cell dyscrasias, the aim of this study was to correlate splenic (68)Ga-Pentixafor uptake in multiple myeloma (MM) with clinical parameters and to evaluate its prognostic impact. Methods: Eighty-seven MM patients underwent molecular imaging with (68)Ga-Pentixafor-PET/CT. Splenic CXCR4 expression was semi-quantitatively assessed by peak standardized uptake values (SUV(peak)) and corresponding spleen-to-bloodpool ratios (TBR) and correlated with clinical and prognostic features as well as survival parameters. Results: (68)Ga-Pentixafor-PET/CT was visually positive in all MM patients with markedly heterogeneous tracer uptake in the spleen. CXCR4 expression determined by (68)Ga-Pentixafor-PET/CT corresponded with advanced disease and was inversely associated with the number of previous treatment lines as compared to controls or untreated smouldering multiple myeloma patients (SUV(peak)Spleen 4.06 ± 1.43 vs. 6.02 ± 1.16 vs. 7.33 ± 1.40; P < 0.001). Moreover, reduced splenic (68)Ga-Pentixafor uptake was linked to unfavorable clinical outcome. Patients with a low SUV(peak)Spleen (<3.35) experienced a significantly shorter overall survival of 5 months as compared to 62 months in patients with a high SUV(peak)Spleen >5.79 (P < 0.001). Multivariate Cox analysis confirmed SUV(peak)Spleen as an independent predictor of survival (HR 0.75; P = 0.009). Conclusion: These data suggest that splenic (68)Ga-Pentixafor uptake might provide prognostic information in pre-treated MM patients similar to what was reported for diffusion-weighted magnetic resonance imaging. Further research to elucidate the underlying biologic implications is warranted. Ivyspring International Publisher 2022-08-08 /pmc/articles/PMC9373803/ /pubmed/35966583 http://dx.doi.org/10.7150/thno.75847 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Kraus, Sabrina
Klassen, Philipp
Kircher, Malte
Dierks, Alexander
Habringer, Stefan
Gäble, Alexander
Kortüm, Klaus Martin
Weinhold, Niels
Ademaj-Kospiri, Valëza
Werner, Rudolf A
Schirbel, Andreas
Buck, Andreas K
Herhaus, Peter
Wester, Hans-Jürgen
Rosenwald, Andreas
Weber, Wolfgang A
Einsele, Hermann
Keller, Ulrich
Rasche, Leo
Lapa, Constantin
Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis
title Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis
title_full Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis
title_fullStr Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis
title_full_unstemmed Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis
title_short Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis
title_sort reduced splenic uptake on (68)ga-pentixafor-pet/ct imaging in multiple myeloma - a potential imaging biomarker for disease prognosis
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373803/
https://www.ncbi.nlm.nih.gov/pubmed/35966583
http://dx.doi.org/10.7150/thno.75847
work_keys_str_mv AT kraussabrina reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis
AT klassenphilipp reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis
AT kirchermalte reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis
AT dierksalexander reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis
AT habringerstefan reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis
AT gablealexander reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis
AT kortumklausmartin reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis
AT weinholdniels reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis
AT ademajkospirivaleza reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis
AT wernerrudolfa reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis
AT schirbelandreas reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis
AT buckandreask reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis
AT herhauspeter reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis
AT westerhansjurgen reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis
AT rosenwaldandreas reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis
AT weberwolfganga reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis
AT einselehermann reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis
AT kellerulrich reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis
AT rascheleo reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis
AT lapaconstantin reducedsplenicuptakeon68gapentixaforpetctimaginginmultiplemyelomaapotentialimagingbiomarkerfordiseaseprognosis